The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 15, 2028

Study Completion Date

March 15, 2028

Conditions

Fabry Disease

Interventions

DRUG

EXG110 Injection

EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.

Trial Locations (3)

General Hospital of Eastern Theater Command, Nanjing

Children's Hospital Zhejiang University School of Medicine, Hangzhou

First Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors

lead

Hangzhou Jiayin Biotech Ltd

INDUSTRY

NCT06819514 - The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease | Biotech Hunter | Biotech Hunter